



Clinical study	PI (Institution)	Disease area	Target enrollment	NCT number and study objectives
<p>Hookipa Pharma Target HPV¹</p> <p>A randomized phase I/II trial of TheraT[®] vectors expressing HPV16 specific antigens in combination with neoadjuvant chemotherapy followed by transoral robotic surgery or risk/response stratified chemoradiotherapy for locoregional HPV16+ oropharyngeal cancer</p>	<p>Ari Rosenberg, MD (University of Chicago)</p>	<p>OPSCC</p>	<p>60 patients/ 600 samples</p>	<p>NCT05108870</p> <p>Primary:</p> <p>Phase 1: Safety/tolerability and recommended phase 2 dose of HB-200 with chemotherapy</p> <p>Phase 2: Deep response rate as assessed by tumor shrinkage according to RECIST v1.1</p> <p>Secondary:</p> <ul style="list-style-type: none"> a) Correlation between plasma HPV-DNA and tumor HPV-DNA b) Changes in plasma HPV-DNA during study treatment with HB-201 and alternating HB201/202 combined with chemotherapy c) Pathologic response in patients undergoing transoral robotic surgery d) PFS e) OS f) Locoregional control
<p>Optima 2B²</p> <p>Pilot study of induction chemotherapy followed by risk and response-stratified treatment for locoregional HPV associated oropharyngeal cancer</p>	<p>Nishant Agrawal, MD Ari Rosenberg, MD (University of Chicago)</p>	<p>OPSCC</p>	<p>47 patients/ 423 samples</p>	<p>NCT04572100</p> <p>Primary:</p> <ul style="list-style-type: none"> a) Feasibility of collection of serial HPV-DNA blood samples in OPSCC patients undergoing treatment b) Evaluate relationship between HPV-DNA found in patient's blood and patient response to chemotherapy <p>Secondary:</p> <ul style="list-style-type: none"> a) Changes in blood containing HPV-DNA during response-based therapy b) Side effects of cisplatin-based chemotherapy treatment c) Tumor response among patients undergoing transoral robotic surgery d) Time to disease recurrence e) OS f) Locoregional control g) Distant control
<p>JHU HPV-SEQ IIS³</p> <p>A novel pilot study of ctHPV DNA as a dynamic, quantitative biomarker of treatment response in OPSCC</p>	<p>Tanguy Seiwert, MD (Johns Hopkins University)</p>	<p>OPSCC</p>	<p>17 patients/ 125 samples</p>	<p>Primary:</p> <p>To characterize ctHPV DNA kinetics during definitive non-surgical management (induction chemotherapy followed by radiation therapy) of HPV-associated OPSCC patients undergoing routine standard of care treatment</p> <p>Secondary:</p> <ul style="list-style-type: none"> a) To identify a post-induction chemotherapy ctHPV DNA percentage clearance threshold that predicts for accelerated complete clearance of ctHPV DNA during chemoradiation in HPV-related oropharyngeal cancer patients b) To correlate ctHPV DNA changes with standard of care radiographic assessment of treatment response c) To investigate relationship between ctHPV DNA clearance at the end of treatment and 2-year PFS for HPV-related oropharyngeal cancer



Learn more:
sysmex-inostics.com/cfhpv-dna-assay



Clinical study	PI (Institution)	Disease area	Target enrollment	NCT number and study objectives
<p>ECOG-ACRIN HPV-SEQ^{4,5}</p> <p>A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients</p>	<p>Cathy Eng, MD (Vanderbilt University)</p>	<p>Anal</p>	<p>200 patients/ 1,000 samples</p>	<p>NCT04444921</p> <p>Primary:</p> <p>To demonstrate that anti-PD-1 therapy (Nivolumab) + carboplatin/weekly paclitaxel results in improved PFS vs systemic therapy alone</p> <p>Secondary:</p> <ul style="list-style-type: none"> a) To demonstrate that experimental arm results in improved OS and ORR using RECIST v1.1 vs systemic therapy alone b) To evaluate toxicity of the two regimens c) To evaluate the role of tumor-derived cell-free ctDNA in monitoring treatment response
<p>JHU Cervical Cancer IIS³</p> <p>A novel pilot study of ctHPV DNA as a dynamic, quantitative biomarker of treatment response in cervical cancer</p>	<p>Akila Viswanathan, MD MPH (Johns Hopkins University)</p>	<p>Cervical</p>	<p>30 patients/ 300 samples</p>	<p>Primary:</p> <p>To characterize ctHPV DNA kinetics during definitive non-surgical management</p> <p>Secondary:</p> <ul style="list-style-type: none"> a) To identify ctHPV DNA percentage clearance threshold after external beam radiation therapy with concurrent chemotherapy that predicts for complete clearance of ctHPV DNA during the brachytherapy course in HPV-related cervical cancer patients b) To correlate ctHPV DNA changes with standard of care radiographic assessment of treatment response after external beam radiation therapy and at 3 months after completion of all therapy c) To investigate relationship between ctHPV DNA clearance at the end of treatment and 2-year PFS



Learn more:
sysmex-inostics.com/cfhpv-dna-assay



ct, circulating tumor; ECOG-ACRYN, Eastern Cooperative Oncology Group-the American College of Radiology Imaging Network; HPV, human papillomavirus; IIS, investigator-initiated study; NCT, national clinical trial; OPSCC, oropharyngeal squamous cell carcinoma; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death protein-1; PFS, progression-free survival; PI, principal investigator; RECIST, Response Evaluation Criteria in Solid Tumors; SEQ, sequencing.
⁴Patient enrollment initiated in Feb 2024.

References: 1. ClinicalTrials.gov identifier: NCT05108870. Updated August 29, 2023. Accessed April 30, 2024. Available at: <https://clinicaltrials.gov/study/NCT05108870>. 2. ClinicalTrials.gov identifier: NCT04572100. Updated July 7, 2023. Accessed April 30, 2024. Available at: <https://clinicaltrials.gov/study/NCT04572100>. 3. JHU Approved IRB protocol document #IRB00289711. 4. ClinicalTrials.gov identifier: NCT04444921. Updated April 30, 2024. Accessed April 30, 2024. Available at: <https://clinicaltrials.gov/study/NCT04444921>. 5. Roth MT et al. J Clin Onc. 2021;39(supplement_15):TPS3614.

Systemx Inostics, Inc. 1812 Ashland Ave, Suite 500, Baltimore, MD 21205, USA
 info@sysmex-inostics.com
www.sysmex-inostics.com

310_HPVC LISTUD_FLY.0324

© 2024 Systemx Inostics, Inc. Plasma-Safe-Seq panels are Laboratory Developed Tests (LDTs) supplied by Systemx Inostics, Inc. at their CLIA-certified laboratory in Baltimore, Maryland, and have not been cleared or approved by the US Food and Drug Administration. Plasma-Safe-Seq panels are not intended for first-line oncology screening or diagnosis and should be used in conjunction with other patient information to help inform clinical decision-making. Performance characteristics needed for clinical use available upon request.